Methods of lowering the error rate of massively parallel DNA sequencing using duplex consensus sequencing

12258,629

16/503398

July 03, 2019

Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (Seattle, WA, US)

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (Seattle, WA, US)

1. A method of sequencing DNA comprising: preparing a sequencing library from a sample comprising a plurality of double-stranded DNA fragments, wherein preparing the sequence library comprises ligating adapter molecules to the plurality of double-stranded DNA fragments to generate a plurality of double-stranded adapter-DNA molecules; sequencing first and second strands of the adapter-DNA molecules to provide a first strand sequence read derived from an original first strand and a distinct, yet related second strand sequence read derived from an original second strand for individual adapter-DNA molecules in the plurality; for at least some of the adapter-DNA molecules: comparing the first strand sequence read with the distinct, yet related second strand sequence read; and generating a consensus sequence of the double-stranded DNA fragment wherein each position in the consensus sequence is identified as correct if the particular position in the first strand sequence read and the particular position in the distinct, yet related second strand sequence read is in agreement.

2. The method of claim 1 , wherein nucleotide bases that are in agreement between the first strand sequence read and the distinct, yet related second strand sequence read are not present in a reference sequence, and wherein said nucleotide bases are identified as a true variant.

3. The method of claim 1 , wherein a nucleotide base that is not in agreement between the first strand sequence read and the distinct, yet related second strand sequence read is identified as a potential artifact.

4. The method of claim 1 , wherein prior to sequencing, the method further comprises amplifying each original strand of the adapter-DNA molecules, resulting in a set of copies of the original first strand of each adapter-DNA molecule and a set of copies of the original second strand of each adapter-DNA molecule, and wherein the sequencing step further comprises sequencing the set of copies of the original first strand and the set of copies of the original second strand to generate a set of first strand sequence reads and a set of distinct, yet related second strand sequence reads.

5. The method of claim 4 , wherein a nucleotide base is not in agreement between the first strand sequence read and the distinct, yet related second strand sequence read, and wherein the method further comprises identifying the internal consistency of base calls among the set of sequence reads derived from each single original strand, and wherein a non-consistent nucleotide base is characterized as (i) a processing error if the base call is not consistent among the set of sequence reads derived from the single original strand, and the non-consistent nucleotide base is characterized as (ii) a site of DNA damage if the base call is consistent among the set of sequence reads derived from the single original strand.

6. The method of claim 1 , wherein prior to comparing the first strand sequence read and the second strand sequence read, the method comprises associating the first strand sequence read with the second strand sequence read using one or more of an adapter sequence, sequence read length, and original strand information.

7. The method of claim 1 , further comprising identifying a mutation occurring at a particular position or region in the consensus sequence as a true mutation.

8. The method of claim 1 , wherein the sample is or comprises double-stranded DNA fragments from a cancer tissue, healthy tissue, or a combination thereof.

9. The method of claim 1 , wherein the plurality of double-stranded adapter-DNA molecules comprise a nucleotide sequence asymmetry such that the original second strand generates the distinct, yet related second strand sequence read when compared to the first strand sequence read.

10. The method of claim 1 , wherein the adapter molecules further comprise a nucleotide sequence that differentiates each original strand relative to its original complementary strand.

11. The method of claim 1 , further comprising comparing the consensus sequence with a reference sequence and identifying a variant occurring at a particular position in the consensus sequence.

12. The method of claim 11 , further comprising identifying the double-stranded DNA fragments as being derived from a neoplastic cell by the variant.

13. The method of claim 1 , further comprising aligning the consensus sequence with a reference sequence and identifying a nucleotide sequence occurring at a particular position or region in the consensus sequence as a true nucleotide sequence.

14. The method of claim 1 , wherein the plurality of double-stranded DNA fragments are circulating nucleic acid molecules.

15. The method of claim 14 , wherein the circulating nucleic acid molecules comprise nucleic acid-based biomarkers from serum or plasma.

16. The method of claim 1 , wherein the sample is a biological sample from a subject, and wherein the method further comprises detecting a cancer, a cancer risk, a cancer metabolic state, or a mutator phenotype in the subject by detecting a cancer-associated nucleic acid-based serum biomarker in the subject.

17. The method of claim 1 , wherein the sample comprises a blood sample or a tissue sample from a subject.

18. A method of sequencing DNA comprising: ligating adapter molecules comprising a region of non-complementarity to a plurality of target double-stranded DNA fragments to generate a plurality of double-stranded adapter-DNA molecules; amplifying an original first strand and an original second strand of at least some of the double-stranded adapter-DNA molecules, resulting in a set of copies of the original first strand and a set of copies of the original second strand; for the at least some of the adapter-DNA molecules: sequencing the set of copies of the original first strand and the set of copies of the original second strand to generate a set of first strand sequence reads and a set of second strand sequence reads that are distinguishable from the set of first strand sequence reads by the region of non-complementarity; and confirming the presence of at least one sequence read derived from each of the original first strand and the original second strand of the adapter-DNA molecule; comparing the first strand sequence read with the second strand sequence read; and generating a consensus sequence of the target double-stranded DNA fragment wherein each position in the consensus sequence is identified as correct if the particular position in the first strand sequence read and the second strand sequence read is in agreement.

19. The method of claim 18 , wherein prior to amplifying an original first strand and an original second strand of at least some of the double-stranded adapter-DNA molecules, the method further comprises selectively enriching the double-stranded adapter-DNA molecules to generate a subset of double-stranded adapter-DNA molecules for sequencing.

20. The method of claim 19 , wherein selectively enriching the adapter-DNA molecules comprises selecting the adapter-DNA molecules based on a strand size.

21. The method of claim 19 , wherein selectively enriching the adapter-DNA molecules occurs via primer extension capture or target DNA amplification.

22. The method of claim 19 , wherein selectively enriching the adapter-DNA molecules comprises amplification of select adapter-DNA molecules with one or more primers specific to each genetic locus in a set of genetic loci among a larger set of genetic sequences in a sample.

23. The method of claim 18 , wherein prior to ligating adapter molecules to the plurality of target double-stranded DNA fragments, the method further comprises selectively enriching target double-stranded DNA fragments by size selection.

24. The method of claim 18 , further comprising comparing the consensus sequence to a reference sequence and identifying a variant occurring at a particular position in the consensus sequence.

25. The method of claim 24 , further comprising identifying the target double-stranded DNA fragments as being derived from a neoplastic cell by the variant.

26. The method of claim 24 , wherein the plurality of target double-stranded DNA fragments are circulating nucleic acid molecules.

27. The method of claim 18 , wherein the target double-stranded DNA fragments comprise nucleic acid-based biomarkers from serum or plasma.

28. The method of claim 18 , wherein the target double-stranded DNA fragments are derived from a biological sample comprising a blood sample or a tissue sample from a subject, and wherein the method further comprises detecting a cancer, a cancer risk, a cancer metabolic state, or a mutator phenotype in the subject by detecting a cancer-associated nucleic acid-based biomarker in the subject.

29. The method of claim 18 , wherein the adapters comprise one or more single molecule identifiers (SMIs) having a degenerate or semi-degenerate sequence.

30. The method of claim 29 , wherein the degenerate or semi-degenerate sequence comprises 2 or more nucleotide bases.

31. The method of claim 29 , wherein each adapter comprises an SMI in at least one of a double-stranded portion or a single-stranded portion of the adapter.

32. The method of claim 18 , wherein after amplifying an original first strand and an original second strand of at least some of the double-stranded adapter-DNA molecules, the method further comprises selectively enriching the double-stranded adapter-DNA molecules to generate a subset of double-stranded adapter-DNA molecules for sequencing.

33. The method of claim 32 , wherein selectively enriching the double-stranded adapter-DNA molecules comprises annealing adapter-DNA strands having a desired DNA sequence by targeted hybridization to oligonucleotides with complementarity to the desired DNA sequence.

34. The method of claim 32 , wherein selectively enriching the adapter-DNA molecules comprises providing an array of capture probes, wherein a plurality of the probes in the array each hybridizes to a DNA sequence that maps to a genetic locus in the reference genome.

5308751 May 1994 Ohkawa et al.
6251610 June 2001 Gupte et al.
6498023 December 2002 Abarzua
6582908 June 2003 Fodor et al.
6958225 October 2005 Dong
7214490 May 2007 Su et al.
7267966 September 2007 Dong et al.
7297778 November 2007 Matsuzaki et al.
7406385 July 2008 Sorenson
7452699 November 2008 Makrigiorgos et al.
7459273 December 2008 Jones et al.
7476503 January 2009 Turner et al.
7741463 June 2010 Gormley et al.
7754429 July 2010 Rigatti
8029993 October 2011 Mikawa
8148068 April 2012 Brenner et al.
8153375 April 2012 Travers et al.
8318434 November 2012 Cuppens
8715967 May 2014 Casbon et al.
8732064 May 2014 Micklem et al.
8741606 June 2014 Casbon et al.
9080210 July 2015 Van Eijk et al.
9085798 July 2015 Chee
9249460 February 2016 Pushkarev et al.
9260753 February 2016 Xie et al.
9476095 October 2016 Vogelstein et al.
9598731 March 2017 Talasaz
9745627 August 2017 Van Eijk et al.
9752188 September 2017 Schmitt et al.
9783847 October 2017 Chee
9834822 December 2017 Talasaz
9862995 January 2018 Patel
9898577 February 2018 Van Eijk et al.
9920366 March 2018 Eltoukhy et al.
10000800 June 2018 Chee
10011871 July 2018 Bielas
10023907 July 2018 Van Eijk et al.
10119165 November 2018 Chee
10202646 February 2019 Fodor et al.
10266883 April 2019 Chee
10266884 April 2019 Chee
10287630 May 2019 Xie et al.
10287631 May 2019 Salk et al.
10501793 December 2019 Chee
10604804 March 2020 Salk et al.
10689699 June 2020 Salk et al.
10711304 July 2020 Salk
10752951 August 2020 Salk et al.
10760127 September 2020 Salk et al.
2003/0165923 September 2003 Li et al.
2004/0209299 October 2004 Pinter et al.
2005/0100900 May 2005 Kawashima et al.
2007/0020640 January 2007 McCloskey et al.
2007/0128624 June 2007 Gormley et al.
2007/0172839 July 2007 Smith et al.
2007/0172873 July 2007 Brenner et al.
2008/0167195 July 2008 Li et al.
2008/0261204 October 2008 Lexow
2009/0093378 April 2009 Bignell
2009/0233802 September 2009 Bignell et al.
2009/0298075 December 2009 Travers
2010/0069263 March 2010 Shendure et al.
2010/0222238 September 2010 Smith et al.
2011/0160078 June 2011 Fodor et al.
2011/0301042 December 2011 Steinmann et al.
2012/0058468 March 2012 McKeown
2012/0071331 March 2012 Casbon et al.
2012/0094847 April 2012 Warthmann et al.
2012/0165202 June 2012 Porreca et al.
2012/0208724 August 2012 Steemers et al.
2012/0220494 August 2012 Samuels et al.
2012/0238738 September 2012 Hendrickson et al.
2012/0244525 September 2012 Hendrickson
2012/0322666 December 2012 Pham et al.
2013/0116417 May 2013 Krauss et al.
2014/0057799 February 2014 Johnson et al.
2014/0134610 May 2014 Pham et al.
2014/0155274 June 2014 Xie
2014/0329282 November 2014 Nelson et al.
2014/0329698 November 2014 Bignell et al.
2015/0024950 January 2015 Bielas
2015/0299812 October 2015 Talasaz
2016/0026758 January 2016 Jabara et al.
2016/0319345 November 2016 Gnerre et al.
2017/0247687 August 2017 Shendure
2018/0023135 January 2018 Van Eijk et al.
2018/0363048 December 2018 Bielas
2018/0363049 December 2018 Bielas
2018/0363051 December 2018 Salk et al.
2018/0363052 December 2018 Salk et al.
2018/0363053 December 2018 Salk et al.
2019/0093160 March 2019 Salk et al.
2019/0093161 March 2019 Salk et al.
2019/0093162 March 2019 Salk et al.
2019/0119748 April 2019 Salk et al.
2019/0119749 April 2019 Salk et al.
2019/0177803 June 2019 Talasaz
2019/0271040 September 2019 Salk et al.
2019/0284626 September 2019 Salk et al.
2019/0284627 September 2019 Salk et al.
2019/0292597 September 2019 Salk et al.
2019/0323082 October 2019 Salk et al.
2019/0338358 November 2019 Salk et al.
2020/0048701 February 2020 Chee
2020/0048702 February 2020 Chee
2020/0048703 February 2020 Chee
2020/0087736 March 2020 Talasaz
2020/0115746 April 2020 Talasaz
2020/0318185 October 2020 Salk et al.
2020/0392580 December 2020 Salk et al.
2021/0277467 September 2021 Vogelstein
2021/0324470 October 2021 Salk et al.
2021/0371920 December 2021 Salk et al.
2021/0371921 December 2021 Salk et al.
2021/0371922 December 2021 Salk et al.
2021/0371923 December 2021 Salk et al.
2021/0371924 December 2021 Salk et al.
2021/0381048 December 2021 Salk et al.
2022/0010376 January 2022 Salk et al.
2022/0017961 January 2022 Salk et al.
2022/0195523 June 2022 Salk et al.
2022/0290231 September 2022 Salk et al.
2024/0035088 February 2024 Salk et al.
2024/0084385 March 2024 Salk et al.
2893040 February 2019
2006113422 October 2006
2011021102 February 2011
2012042374 April 2012
2012061832 May 2012
2012129363 September 2012
WO-2013123442 August 2013
2013142389 September 2013
2015100427 July 2015
2017100441 June 2017

Kinde et al. (PNAS, 2011, 108(23):9530-9535, cited in IDS) (Year: 2011). cited by examiner
Travers et al. Nucleic Acids Reserach, 2010, 38(15):e159, pp. 1-8 (Year: 2010) cited by examiner
Ameur A, Stewart JB, Freyer C, Hagstrom E, Ingman M, Larsson N-G, et al. UltraDeep Sequencing of Mouse Mitochondrial DNA: Mutational Patterns and Their Origins. PLoS Genet. 2011;7:e1 002028. cited by applicant
Bainbridge MN, Wang M, Burgess DL, Kovar C, Rodesch M, D'Ascenzo M, et al. Whole exome capture in solution with 3 Gbp of data. Genome Bioi. 2010;11: R62:1-8. cited by applicant
Boyd SO, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B, et al. Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing. Science Translational Medicine. 2009;1 :12ra23-12ra23. cited by applicant
Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA. 2008; 105:13081-6. cited by applicant
Carlson CA, Kas A, Kirkwood R, Hays LE, Preston BD, Salipante SJ, et al. Decoding cell lineage from acquired mutations using arbitrary deep sequencing. Nat Methods. 2012;9:78-80. cited by applicant
Casbon JA, Osborne RJ, Brenner S, Lichtenstein CP. A method for counting PCR template molecules with application to next-generation sequencing. Nucleic Acids Research. 2011;39:e81-e. cited by applicant
Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ. Embryonic stem cells and somatic cells differ in mutation frequency and type. Proc Natl Acad Sci USA. 2002;99:3586-90. cited by applicant
Chiu RWK, Akolekar R, Zheng YWL, Leung TY, Sun H, Chan KCA, et al. Noninvasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ. 2011 ;342:c7401. cited by applicant
De Grassi A, Segala C, Iannelli F, Volorio S, Bertario L, Radice P, et al. Ultradeep Sequencing of a Human Ultraconserved Region Reveals Somatic and Constitutional Genomic Instability. PLoS Biol. 2010;8:e1000275. cited by applicant
Ding L, Ley T J, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 21 05;481:506-9. cited by applicant
Druley TE, Vallania FLM, Wegner OJ, Varley KE, Knowles OL, Bonds JA, et al. Quantification of rare allelic variants from pooled genomic DNA, Nat Methods. 2009;6 :263-5. cited by applicant
Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obsbet Gynecol. 2011;204:205e1-11. cited by applicant
European Patent Office, Extended European Search Report for EP13764186.6, dated Sep. 8, 2015, 3 pages. cited by applicant
European Patent Office, Examination Report for EP13764186.6, dated May 13, 2016, 6 pages. cited by applicant
European Patent Office, Examination Report for EP13764186.6, dated Jan. 31, 2017, 7 pages. cited by applicant
European Patent Office, Examination Report for EP13764186.6, dated Aug. 10, 2017, 7 pages. cited by applicant
European Patent Office, Examination Report for EP13764186.6, dated Jun. 8, 2018, 5 pages. cited by applicant
European Patent Office, Examination Report for EP13764186.6, dated Oct. 4, 2018, 6 pages. cited by applicant
Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake Sr. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA. 2008;105:16266-71. cited by applicant
Flaherty P, Natsoulis G, Muralidharan O, Winters M, Buenrostro J, Bell J, et al. Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Research. 2012;40:e2-e. cited by applicant
Fordyce SL, Avila-Areas MC, Rockenbauer E, B0rsting C, Frank-Hansen R, Petersen FT, et al. High-throughput sequencing of core STR loci for forensic genetic investigations using the Roche Genome Sequencer FLX platform. BioTechniques. 2011;51 :127-33. cited by applicant
Fu GK, Hu J, Wang P-H, Fodor SPA. Counting individual DNA molecules by the stochastic attachment of diverse labels. Proc Natl Acad Sci USA. 2011;108:9026-31. cited by applicant
Garcia-Garcera M, Gigli E, Sanchez-Quinto F, Ramirez O, Calafell F, Civit S, et al. Fragmentation of contaminant and endogenous DNA in ancient samples determined by shotgun sequencing; prospects for human palaeogenomics. PLoS ONE. 2011;6:e24161. cited by applicant
Greaves LC, et al. (2009) Quantification of mitochondrial DNA mutation load. Aging Cell 8:566-572. cited by applicant
Haag-Liautard C, et al. (2008) Direct estimation of the mitochondrial DNA mutation rate in Drosophila melanogaster. PLoS Bioi 6:e204. cited by applicant
He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE, et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature. 2010;464:610-4. cited by applicant
Howell N, Kubacka I, Mackey DA (1996) How rapidly does the human mitochondrial genome evolve? Am J Hum Genet 59:501-509. cited by applicant
Hyman RW, Herndon CN, Jiang H, Palm C, Fukushima M, Bernstein D, et al. The dynamics of the vaginal microbiome during infertility therapy with in vitro fertilization embryo transfer. J Assist Reprod Genet. 2012;29:105-15. cited by applicant
Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA. 2011;108:20166-71. cited by applicant
Jazin EE, Cavelier L, Eriksson I, Oreland L, Gyllensten U (1996) Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. Proc Natl Acad Sci USA 93:12382-12387. cited by applicant
Kanagawa T. Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng. 2003;96:317-23. cited by applicant
Kasai H, et al.(1993) Formation, inhibition of formation, and repair of oxidative 8-hydroxyguanine DNA damage. Basic Life Sci 61:257-262. cited by applicant
Kaur M, Makrigiorgos GM. Novel amplification of DNA in a hairpin structure: towards a radical elimination of PCR errors from amplified DNA. Nucleic Acids Res. 2003;31:26e1-7. cited by applicant
Kennedy SR, Loeb LA, Herr AJ (2012) Somatic mutations in aging, cancer and neurodegeneration. Mech Ageing Dev 133(4):118-26. cited by applicant
Khaidakov M, Heflich RH, Manjanatha MG, Myers MB, Aidoo A (2003) Accumulation of point mutations in mitochondrial DNA of aging mice. Mutat Res 526:1-7. cited by applicant
Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108:9530-5. cited by applicant
Kivioja et al., “Counting absolute numbers of molecules using unique molecular identifiers,” Nature Methods 9, dated Jan. 1, 2012, pp. 72-74. cited by applicant
Kozarewa I, Ning Z, Quail MA, Sanders MJ, Berriman M, Turner OJ. Amplification free Illumine sequencing-library preparation facilitates improved mapping and assembly of (G+C)-biased genomes. Nat Methods. 2009; 6:291-5. cited by applicant
Kraytsberg Y, Nicholas A, Caro P, Khrapko K (2008) Single molecule PCR in mtDNA mutational analysis: Genuine mutations vs. damage bypass-derived artifacts. Methods 46:269-273. cited by applicant
Kunkel, TA. Mutational specificity of depurination. Proc Natl Acad Sci USA. 1984; 81:1494-98. cited by applicant
LaTuga MS, Ellis JC, Cotton CM, Goldberg RN, Wynn JL, Jackson RB, et al. Beyond bacteria: a study of the enteric microbial consortium in extremely low birth weight infants. PLoS ONE. 2011; 6:e27858. cited by applicant
Lecroq B, Lejzerowicz F, Bechar D, Christen R, Esling P, Baerlocher L, et al. Ultradeep sequencing of foraminiferal microbarcodes unveils hidden richness of early monothalamous lineages in deep-sea sediments. Proc Natl Acad Sci USA. 2011;108:13177-82. cited by applicant
Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF (2002) High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 11:133-145. cited by applicant
Lindahl T, Wood RD. Quality control by DNA repair. Science. 1999;286:1897-1905. cited by applicant
Lynch AM, Sasaki jC, Elespuru R, Jacobson-Kram D, Thybaud V, et al. New and emerging technologies for genetic toxicity testing. Environ Mol Mutagen. 2011;52(3):205-23. cited by applicant
Mackelprang R, Waldrop MP, DeAngelis KM, David MM, Chavarria KL, Blazewicz SJ, et al. Metagenomic analysis of a permafrost microbial community reveals a rapid response to thaw. Nature. 2011 ;480:368-71. cited by applicant
McBride T J, Preston BD, Loeb LA (1991) Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry 30:207-213. cited by applicant
McCloskey ML, Stager R, Hansen RS, Laird CD. Encoding PCR products with batch-stamps and barcodes. Biochem Genet. 2007; 45:761-7. cited by applicant
Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11:31-46. cited by applicant
Meyerhans A, Vartanian JP, Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Research. 1990;18:1687-91. cited by applicant
Miner BE, Stager RJ, Burden AF, Laird CD, Hansen RS. Molecular barcodes detect redundancy and contamination in hairpin-bisulfite PCR. Nucleic Acids Research. 2004;32:e135. cited by applicant
Minot S, Sinha R, Chen J, Li H, Keilbaugh SA, Wu GO, et al. The human gut virome: interindividual variation and dynamic response to diet. Genome Res. 2011; 21:1616-25. cited by applicant
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 105:10513-8. cited by applicant
Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE. 2011;6:e24907. cited by applicant
Out AA, van Minderhout IJHM, Goeman JJ, Ariyurek Y, Ossowski S, Schneeberger K, et al. Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat. 2009;30:1703-12. cited by applicant
Ozsolak, F., Platt, A.R., Jones, D.R., Reifenberger, J.G., Sass, L.E., Mcinerney, P., Thompson, J.F., Bowers, J., Jarosz, M., and Milos, P.M. (2009). Direct RNA sequencing. Nature 461, 814-818. cited by applicant
Parsons T J, et al. (1997) A high observed substitution rate in the human mitochondrial DNA control region. Nat Genet 15:363-368. cited by applicant
Quail MA, Kozarewa I, Smith F, Scally A, Stephens PJ, Durbin R, et al. A large genome center's improvements to the Illumina sequencing system. Nat Methods. 2008;5:1005-10. cited by applicant
Roberts et al., “Short template amplicon and multiplex megaprimer-enabled relay (STAMMER) sequencing, a simultaneous approach to higher throughput sequence-based typing of polymorphic genes”, Immunogenetics (2010), vol. 62, 253-60. cited by applicant
Salk J, Fox E, Loeb L. Mutational heterogeneity in human cancers: origin and consequences. Annual Review of Pathology. 2009;5:51-75. cited by applicant
Shen Y, Wan Z, Coarfa C, Drabek R, Chen L, Ostrowski EA, et al. A SNP discovery method to assess variant allele probability from next-generation resequencing data. Genome Res. 2010;20:273-80. cited by applicant
Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135-45. cited by applicant
Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature. 1991;349:431-4. cited by applicant
Shiroguchi et al., “Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes”, PNAS 109, dated Jan. 9, 2012, pp. 1347-1652. cited by applicant
Song S, et al. (2005) DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 102:4990-4995. cited by applicant
Stiller M, Green RE, Ronan M, Simons JF, Du L, HeW., et al. Patterns of nucleotide misincorporations during enzymatic amplification and direct large-scale sequencing of ancient DNA. Proc Natl Aced Sci USA. 2006; 103:13578-84. cited by applicant
Stoneking M (2000) Hypervariable sites in the mtDNA control region are mutational hotspots. Am J Hum Genet 67:1029-1032. cited by applicant
Thomas DC, Roberts JD, Sabatino RD, Myers TW, et al. Fidelity of mammalian DNA replication and replicative DNA polymerases. Biochemistry. 1991;30:11751-9. cited by applicant
Travers KJ, Chin CS, Rank DR, Eid JS, Turner SW. A flexible and efficient template format for circular consensus sequencing and SNP detection. Nucleic Acids Res. 2010; 38:159e1-8. cited by applicant
USPTO, International Search Report and Written Opinion for PCT/US2013/032665, dated Jul. 9, 2013, 14 pages. cited by applicant
USPTO, Notice of Allowance for U.S. Appl. No. 15/660,785, dated Dec. 27, 2018. 17 pages. cited by applicant
USPTO, Non-Final Office Action for U.S. Appl. No. 16/120,019, dated Nov. 19, 2018. 16 pages. cited by applicant
USPTO, Final Office Action for U.S. Appl. No. 16/120,019, dated Jun. 7, 2019. 17 pages. cited by applicant
USPTO, Notice of Allowance for U.S. Appl. No. 16/120,091, dated Mar. 4, 2019. 9 pages. cited by applicant
USPTO, Notice of Allowance for U.S. Appl. No. 16/120,091, dated Jun. 10, 2019. 8 pages. cited by applicant
USPTO, Non-Final Office Action for U.S. Appl. No. 16/411,045, dated Jul. 25, 2019. 20 pages. cited by applicant
Vandenbroucke I, Van Marek H, Verhasselt P, Thys K, Mostmans W, Dumont S, et al. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. BioTechniques. 2011;51 :167-77. cited by applicant
Vermulst M, et al. (2007) Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39:540-543. cited by applicant
Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007;17:1195-201. cited by applicant
Wiemann S, Stegemann J, Grothues D, Bosch A, Estivill X, Schwager C, Zimmermann J, Voss H, Ansorge W. (1995) Simultaneous On-Line DNA Sequencing on Both Strands with Two Fluorescent Dyes. Analytical Biochemistry, vol. 224, pp. 117-121. cited by applicant
Yang J, Yang F, Ren L, Xiong Z, Wu Z, Dong J, et al. Unbiased parallel detection of viral pathogens in clinical samples by use of a metagenomic approach. J Clin Microbial. 2011;49:3463-9. cited by applicant
Zagordi O, Klein R, Daumer M, Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Research. 2010;38:7400-9. cited by applicant
Borodina, T. et al. “Chapter five—A Strand-Specific Library Preparation Protocol for RNA Sequencing” Methods in Enzymology, 2011, vol. 500, pp. 79-98. cited by applicant
EPO, Extended European Search Report for Application No. EP20166917.3, dated Sep. 30, 2020. 6 pages. cited by applicant
USPTO, U.S. Appl. No. 16/411,066, Non-Final Office Action, dated Dec. 23, 2019. 33 pgs. cited by applicant
USPTO, U.S. Appl. No. 16/503,382, Non-Final Office Action, dated Jan. 24, 2020. 35 pgs. cited by applicant
USPTO, U.S. Appl. No. 16/503,382, Notice of Allowance with notice of references cited, dated Jul. 15, 2020. cited by applicant
USPTO, U.S. Appl. No. 16/908,611, Non-Final Office Action, dated Oct. 9, 2020. 28 pages. cited by applicant
Withers & Rogers, Opposition against European Patent No. 2828218, dated May 4, 2021, 28 pages. cited by applicant
Margaret Dixon, Opposition against European Patent No. 2828218, dated May 4, 2021, 23 pages. cited by applicant
Lewis Silkin, Opposition against European Patent No. 2828218, dated May 4, 2021, 7 pages. cited by applicant
Kinde et al., Supporting Information corresponding to “Detection and quantification of rare mutations with massively parallel sequencing”, PNAS USA 108:9530-9535, Jun. 7, 2011. cited by applicant
Schmitt et al., Supporting Information corresponding to “Detection of ultra-rare mutations by next-generation sequencing”, PNAS, Sep. 4, 2012, 109(36) 14508-14513. cited by applicant
Schmitt et al., Corrected Supporting Information corresponding to “Detection of ultra-rare mutations by next-generation sequencing”, PNAS, Sep. 4, 2012, 109(36) 14508-14513, Corrected SI dated Mar. 27, 2013. cited by applicant
Shiroguchi et al., Supporting Information corresponding to “Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes”, PNAS, ePub 109(4): 1347-1352), Jan. 9, 2012. cited by applicant
USPTO, U.S. Appl. No. 16/503,382, Corrected Notice of Allowance with notice of references cited, dated Jul. 29, 2020. cited by applicant
USPTO, U.S. Appl. No. 16/118,306, Non-Final Office Action, dated Nov. 18, 2020. 50 pages. cited by applicant
USPTO, U.S. Appl. No. 16/118,290, Non-Final Office Action, dated Dec. 14, 2020. 33 pages. cited by applicant
USPTO, U.S. Appl. No. 17/008,395, Non-Final Office Action, dated Jan. 7, 2021, 20 pages. cited by applicant
USPTO, U.S. Appl. No. 16/118,305, Non-Final Office Action, dated Jan. 13, 2021. cited by applicant
USPTO, U.S. Appl. No. 16/908,611, Notice of Allowance, dated Jan. 29, 2021. 11 pages. cited by applicant
USPTO, U.S. Appl. No. 16/119,471, Non-Final Office Action, dated Feb. 2, 2021, 32 pages. cited by applicant
USPTO, U.S. Appl. No. 16/118,286, Non-Final Office Action, dated Mar. 1, 2021. cited by applicant
USPTO, U.S. Appl. No. 16/118,306, Final Office Action, dated Mar. 29, 2021. 17 pages. cited by applicant
USPTO, U.S. Appl. No. 17/008,395, Notice of Allowance, dated Apr. 15, 2021, 13 pages. cited by applicant
USPTO, U.S. Appl. No. 16/118,290, Notice of Allowance, dated Apr. 20, 2021. 5 pages. cited by applicant
Bentley, David R. et al., “Accurate whole human genome sequencing using reversible terminator chemistry,” Nature 456:53-59 (2008). cited by applicant
Chiu, R.W.K. et al., “Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma,” PNAS 105:20458-20463 (2008). cited by applicant
Diehl, Frank et al., “Basic-Alimentary Tract-Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients”, Gastroenterology 135:489-498 (2008). cited by applicant
Diehl, Frank et al., “Detection and quantification of mutations in the plasma of patients with colorectal tumors,” PNAS 102:16368-16373 (2005). cited by applicant
Ding, Li et al., “Analysis of next-generation genomic data in cancer: accomplishments and challenges,” Human Molecular Genetics, 19:R188-R196 (2010). cited by applicant
Ewing, B. et al. “Base-Calling of Automated Sequencer Traces Using Phred. II. Error Probabilities” Genome Research (1998) vol. 8, pp. 186-194. cited by applicant
Fleischhacker, M. et al., “Circulating nucleic acids (CNAs) and cancer—A survey,” Biochimica et Biophysica Acta. 1775:181-232 (2007). cited by applicant
Fong, Siew Lee et al., “Comparison of 7 Methods for Extracting Cell-Free DNA from Serum Samples of Colorectal Cancer Patients,” Clinical Chemistry, 55:587-598 (2009). cited by applicant
Forshew, T. et al. “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA” Science Translational Medicine (2012) vol. 4, Issue 136, 136ra68, 14 pages. cited by applicant
Gordon, David J. et al., “Causes and consequences of aneuploidy in cancer,” Nature Reviews Genetics 13:189-203 (2012). cited by applicant
Jiang, Hui et al., “SeqMap: mapping massive amount of oligonucleotides to the genome,” Bioinformatics 24:2395-2396 (2008). cited by applicant
Kao, Wei-Chun et al., “BayesCall: A model-based base-calling algorithm for high-throughput short-read sequencing,” Genome Research 19:1884-1895 (2009). cited by applicant
Kircher, Martin et al., “Improved base calling for the Illumina Genome Analyzer using machine learning strategies,” Genome Biology 10:R83 (2009). cited by applicant
Kirsch, Stefan et al., “Sequence error storms and the landscape of mutations in cancer,” PNAS 109:14289-14290 (2012). cited by applicant
Ledergerber, Christian et al., “Base-calling for next-generation sequencing platforms,” Briefings in Bioinformatics 12:489-497 (2011). cited by applicant
Li, Heng et al., “Fast and accurate short read alignment with Burrows-Wheeler transform,” Bioinformatics 25:1754-1760 (2009). cited by applicant
Li, Heng et al., “Mapping short DNA sequencing reads and calling variants using mapping quality scores,” Genome Research, 18:1851-1858 (2008). cited by applicant
Liang, Kuo-Ching et al., “Bayesian Basecalling for DNA Sequence Analysis Using Hidden Markov Models,” IEEE/ACM Transactions on Computational Biology and Bioinformatics, 4:430-440 (2007). cited by applicant
Liao, Gary J.W. et al., “Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles,” Clinical Chemistry 57:92-101 K2011). cited by applicant
Lo, Y.M. Dennis et al., “Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis,” Am. J. Hum. Genet. 62:768-775 (1998). cited by applicant
Lunter, Gerton et al., “Stampy: A statistical algorithm for sensitive and fast mapping of Illumina sequence reads,” Genome Research 21:936-939 (2011). cited by applicant
McKernan, Kevin Judd et al., “Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding,” Genome Research 19:1527-1541 (2009). cited by applicant
Mertes, Florian et al., “Targeted enrichment of genomic DNA regions for next-generation sequencing,” Briefings in Functional Genomics, 10:374-386 (2011). cited by applicant
Meyer, M. et al. “Targeted high-throughput sequencing of tagged nucleic acid samples” Nucleic Acids Research (2007) vol. 35, No. 15, e97, 5 pages. cited by applicant
Meyerson, Matthew et al., “Advances in understanding cancer genomes through second-generation sequencing,” Nature Reviews Genetics, 11:685-696 (2010). cited by applicant
Narayan, A. et al. “Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing” Cancer Research (2012) vol. 72, No. 14, pp. 3492-3498. cited by applicant
Nielsen, Rasmus et al., “Genotype and SNP calling from next-generation sequencing data,” Nature Reviews Genetics, 12:443-451 (2011). cited by applicant
Quinlan, Aaron R. et al., “Pyrobayes: an improved base caller for SNP discovery in pyrosequences,” Nature Methods, 5:179-181 (2008). cited by applicant
Redon, Richard et al., “Global variation in copy number in the human genome,” Nature 444:444-454 (2006). cited by applicant
Rizzo, J. et al. “Key Principles and Clinical Applications of “Next-Generation” DNA Sequencing” Cancer Prevention Research (2012), vol. 5, No. 7, pp. 887-900. cited by applicant
Schmitt, Michael W. et al., “Detection of ultra-rare mutations by next-generation sequencing,” PNAS 109:14508-14513 (2012). cited by applicant
Schwarzenbach, H. et al., “Cell-free nucleic acids as biomarkers in cancer patients,” Nature Reviews, 11, 426-437, 2011. cited by applicant
Schweiger, Michal R. et al., “Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis,” PLOS One 4:e5548 (2009). cited by applicant
Sehnert, Amy J. et al., “Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood,” Clinical Chemistry 57:1042-1049 (2011). cited by applicant
Sparks, Andrew B., et al., “Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy,” Prenatal Diagnosis, 32:3-9 (2012). cited by applicant
Teer, Jamie K. et al., “Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding,” Genome Research 20:1420-1431 (2010). cited by applicant
USPTO, U.S. Appl. No. 16/120,019, Notice of Allowance, dated Oct. 30, 2019. 15 pgs. cited by applicant
USPTO, U.S. Appl. No. 16/411,045, Notice of Allowance, dated Nov. 15, 2019. 16 pgs. cited by applicant
USPTO, U.S. Appl. No. 16/411,068, Non-Final Office Action, dated Nov. 20, 2019. 28 pgs. cited by applicant
USPTO, U.S. Appl. No. 16/411,069, Non-Final Office Action, dated Nov. 26, 2019. 28 pgs. cited by applicant
Wagle, Nikhil et al., “High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing,” AACR Cancer Discovery 2:82-93 (2011). cited by applicant
USPTO, U.S. Appl. No. 16/119,471, Notice of Allowance, dated May 24, 2021, 11 pages. cited by applicant
USPTO, U.S. Appl. No. 16/118,305, Notice of Allowance, dated Sep. 23, 2021. cited by applicant
USPTO, U.S. Appl. No. 17/361,245, Nonfinal Office Action, dated Nov. 3, 2021. cited by applicant
Craig et al., “Identification of genetic variants using bar-coded multiplexed sequencing,” Nature Methods 5 887-93 + supplemental material (Oct. 2008). cited by applicant
Perakis, S. et al., Advances in Circulating Tumor DNA Analysis, Advances in Clinical Chemistry, vol. 80, 2017. cited by applicant
Withers & Rogers, Further Observations filed in Opposition against European Patent No. 2828218, dated Jan. 19, 2022, 8 pages. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-00449, Paper 3—Petition, Jan. 31, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-00449, Ex. 1002—Quackenbush Declaration, Jan. 31, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-00450, Paper 3—Petition, Jan. 31, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-00450, Ex. 1002—Quackenbush Declaration, Jan. 31, 2022. cited by applicant
USPTO, U.S. Appl. No. 17/392,180, Nonfinal Office Action, mail date Feb. 3, 2022. cited by applicant
USPTO, U.S. Appl. No. 17/392,207, Nonfinal Office Action, mail date: Feb. 18, 2022. cited by applicant
USPTO, U.S. Appl. No. 17/392,185, Nonfinal Office Action, mail date: Feb. 22, 2022. cited by applicant
USPTO, U.S. Appl. No. 17/361,245, Notice of Allowance, mail date: Feb. 25, 2022. cited by applicant
USPTO, U.S. Appl. No. 17/392,203, Nonfinal Office Action, mail date: Mar. 21, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,760,127, IPR2022-00816, Paper 3—Petition, Apr. 8, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,760,127, IPR2022-00816, Ex. 1002—Quackenbush Declaration, Apr. 8, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,760,127, IPR2022-00817, Paper 3—Petition, Apr. 8, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,760,127, IPR2022-00817, Ex. 1002—Quackenbush Declaration, Apr. 8, 2022. cited by applicant
Clark, T. et al. “Direct Detection and Sequencing of Damaged DNA Bases” Genome Integrity, 2011, vol. 2, No. 10, 9 pages. (IPR2022-00817 Ex. 1030). cited by applicant
Evans et al., “NEB Expressions” New England BioLabs (2007) (IPR2022-00816 Ex. 1014). cited by applicant
Hodges et al., “Genome-wide in situ exon capture for selective resequencing,” Nature Genetics 39(12) (2007) (IPR2022-00817 Ex. 1028). cited by applicant
Illumina, Complete Secondary Analysis Workflow for the Genome Analyzer, Technical Note: Illumina Systems and Software (2009) (IPR2022-00816 Ex. 1011). cited by applicant
Illumina, Preparing Samples for Sequencing Genomic DNA (2007) (IPR2022-00816 Ex. 1008). cited by applicant
McCarthy, “Third Generation DNA Sequencing: Pacific Biosciences' Single Molecule Real Time Technology,” Chemistry & Biology 17 (2010) (IPR2022-00817 Ex. 1026). cited by applicant
NEB Expressions, New England BioLabs, https://web.archive.org/web/20080321144426/http://www.neb.com/nebecomm/tech_reference/neb_transcripts.asp (Feb. 23, 2022) (IPR2022-00816 Ex. 1015). cited by applicant
Nisha et al., “Antioxidants and Their Protective Action Against DNA Damage,” International Journal of Pharmacology and Pharmaceutical Sciences 3 (2011) (IPR2022-00816 Ex. 1017). cited by applicant
Song et al., “Sensitive and specific single-molecule sequencing of 5-hydroxymethylcytosine,” Nature Methods 9(1) (2012) (IPR2022-00816 Ex. 1027). cited by applicant
USPTO, U.S. Appl. No. 17/392,175, Nonfinal Office Action, mail date: Dec. 9, 2021. cited by applicant
USPTO, U.S. Appl. No. 17/392,193, Nonfinal Office Action, mail date: Dec. 13, 2021. cited by applicant
USPTO, U.S. Appl. No. 17/392,175, Final Office Action, mail date: Apr. 13, 2022. cited by applicant
Guardant Health, Inc., Response to Notice of Opposition, European Patent No. 2 893 040 (May 2020). cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,752,951, IPR2022-01158, Paper 3—Petition, Jul. 12, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,752,951, IPR2022-01158, Ex. 1002—Quackenbush Declaration, Jul. 12, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,752,951, IPR2022-01159, Paper 3—Petition, Jul. 12, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,752,951, IPR2022-01159, Ex. 1002—Quackenbush Declaration, Jul. 12, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-01388, Paper 2—Petition, Aug. 10, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,689,699, IPR2022-01388, Ex. 1002—Quackenbush Declaration, Aug. 10, 2022. cited by applicant
Guardant Health, Plaintiffs Opening Claim Construction Brief—TwinStrand Biosciences, Inc., & University of Washington v. Guardant Health, Inc., U.S. District Court for the District of Delaware, C.A. No. 21-1126-VAC. Jul. 27, 2022. cited by applicant
Guardant Health, IPR2022-00449, Ex. 1008—EP Application No. 13764186 Prosecution History through Sep. 7, 2020. cited by applicant
Guardant Health, IPR2022-00449, Ex. 1031—U.S. Appl. No. 16/593,633 File History Excerpts, Jan. 31, 2022. cited by applicant
Guardant Health, IPR2022-00449, Ex. 1032—U.S. Appl. No. 16/277,724 Notice of Allowance (dated Jun. 4, 2020). cited by applicant
Guardant Health, IPR2022-00449, Ex. 1033—U.S. Appl. No. 14/712,754 Office Action (dated May 31, 2016). cited by applicant
Guardant Health, IPR2022-00449, Ex. 1038—U.S. Appl. No. 16/672,267 Notice of Allowance (dated Jul. 21, 2021). cited by applicant
Cosmic Data Analyses, Sanger Institute Catalogue of Somatic Mutations in Cancer, obtained from: https://cancer.sanger.ac.uk/cosmic/analyses, Last accessed Jun. 10, 2022. cited by applicant
Krimmel et al., “Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues,” PNAS 113(21) (May 24, 2016). cited by applicant
Wang et al., “Briefing in family characteristics of microRNAs and their applications in cancer research,” Biochimica et Biophysica Acta 1844 (2014). cited by applicant
USPTO, U.S. Appl. No. 17/392,203, Notice of Allowance, mail date: Jul. 14, 2022, 16 pages. cited by applicant
EPO, Application No. EP2828218, Summons to Attend Oral Proceedings and Preliminary, Non-Binding Opinion, Aug. 3, 2022. cited by applicant
Guardant Health, Invalidity Contentions—TwinStrand Biosciences, Inc., & University of Washington v. Guardant Health, Inc., U.S. District Court for the District of Delaware, C.A. No. 21-1126-VAC. May 17, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,287,631, IPR2022-00935, Paper 2—Petition, May 6, 2022. cited by applicant
Guardant Health, Petition for IPR of U.S. Pat. No. 10,287,631, IPR2022-00935, Ex. 1002—Quackenbush Declaration, May 6, 2022. cited by applicant
Minoche et al., “Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and Genome Analyzer systems,” Genome Biology, 12, R112; 1-15. Nov. 8, 2011. cited by applicant
Mattox et al., “Bisulfite-converted duplexes for the strand specific detection and quantification of rare mutations.” PNAS, 114; 4733-4738. Apr. 17, 2017. cited by applicant
USPTO, U.S. Appl. No. 17/392,180, Final Office Action, mail date: Jun. 6, 2022. 32 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,185, Notice of Allowance, mail date: Jun. 10, 2022. 24 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,207, Notice of Allowance, mail date: Jun. 14, 2022. 12 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,175, Notice of Allowance, mail date: Oct. 12, 2022, 16 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,180, Notice of Allowance, mail date: Oct. 13, 2022, 15 pages. cited by applicant
Withers & Rogers (O1), Further Brief Comments filed in Opposition against European Patent No. 2828218, dated Jan. 20, 2023, 11 pages. cited by applicant
Margaret Dixon (O2), Further Comments filed in Opposition against European Patent No. 2828218, dated Jan. 19, 2023, 12 pages. cited by applicant
Lewis Silkin (O3), Further Comments filed in Opposition against European Patent No. 2828218, dated Jan. 20, 2023, 4 pages. cited by applicant
Duncavage et al., “Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia,” Modern Pathology, 25:795-804 (2012). cited by applicant
US District Court, Delaware, Report and Recommendation on Claim Construction by U.S. Magistrate Judge Sherry R. Fallon—TwinStrand Biosciences, Inc., & University of Washington v. Guardant Health, Inc., U.S. District Court for the District of Delaware, C.A. No. 21-1126-VAC, , Dec. 29, 2022. cited by applicant
EPO, Application No. EP20166917.3, Examination Report, dated Mar. 14, 2023, 4 pages. cited by applicant
EPO, Application No. EP13764186.6, Notice of Revocation of Patent No. EP 2828218, dated Mar. 22, 2023, 2 pages. cited by applicant
PTAB, IPR2022-01158, Paper 19, Decision Granting Institution of IPR, Jan. 13, 2023. cited by applicant
PTAB, IPR2022-00817, Paper 14, Decision Granting Institution of IPR, Oct. 13, 2022. cited by applicant
EPO, Application No. EP13764186.6, Decision of Revocation Patent No. EP 2828218 with Written Opinion, dated May 24, 2023, 26 pages. cited by applicant
Guardant Health, IPR2022-00817, Paper 26, Petitioner's Reply re IPR of Patent No. 10,760,127, Apr. 13, 2023. cited by applicant
Guardant Health, IPR2022-00817, Ex. 1033 filed with Petitioner's Reply, Declaration of Dr. Andres Larrea, Apr. 13, 2023. cited by applicant
Guardant Health, IPR2022-00817, Ex. 1037 filed with Petitioner's Reply, Deposition Transcript of Rahul Satija, D. Phil (Mar. 21, 2023). cited by applicant
Guardant Health, IPR2022-00817, Ex. 1039 filed with Petitioner's Reply, Rebuttal Declaration of Dr, John Quackenbush, Apr. 13, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 13, Petitioner's Pre-Institution Reply re IPR of Patent No. 10,752,951, Nov. 22, 2022. cited by applicant
Chin, Chen-Shan et al., “The Origin of the Haitian Cholera Outbreak Strain,” New England J Medicine, 364 (2011), 33-42, + supplemental information (290 pages) (IPR2022-00817 Ex. 1036). cited by applicant
Pacific Biosciences Template Preparation and Sequencing Guide, 2010 (IPR2022-00817 Ex. 1035). cited by applicant
Guo et al., “A randomized lentivirus shRNA library construction,”2007. Biochemical and Biophysical Research Communications, vol. 348, pp. 272-276. (Year: 2007). cited by applicant
Hirst etal., “Next generation sequencing based approaches to epigenomics,” 2010. Briefings in Functional Genomics, vol. 9, Issue 6, pp. 455-465. (Year:2010). cited by applicant
Myllykangas et al., “Overview of Sequencing Technology Platforms,” First Online 2011. Bioinformatics for High Throughput Sequencing, Chapter 2, pp. 11-25. (Year: 2011). cited by applicant
USPTO, U.S. Appl. No. 17/392,203, Nonfinal Office Action, mail date: Oct. 30, 2023, 14 pages. cited by applicant
PTAB, IPR2022-01158, Paper 47, Final Written Decision finding claims 1-28 of U.S. Pat. No. 10,752,951 unpatentable, Jan. 11, 2024. cited by applicant
Guardant Health, IPR2022-00817, Paper 45, Transcript of Oral Hearing held Jun. 15, 2023, Aug. 4, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 33, Petitioner's Reply re IPR of U.S. Pat. No. 10,752,951, Jun. 30, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 33, Exhibit 1062 filed with Petitioner's Reply, Deep Sequence Data Analysis, Springer-Link, https://link.springer.com/book/10.1007/978-1-62703-514-9, (2013), Jun. 30, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 33, Exhibit 1063 filed with Petitioner's Reply, Stoler et al., “Family reunion via error correction: an efficient analysis of duplex sequencing data,” BMC Bioinformatics (2020) Jun. 30, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 33, Exhibit 1063 filed with Petitioner's Reply, Stoler et al., “Streamlined analysis of duplex sequencing data with Du Novo,” Genome Biology (2016), Jun. 30, 2023. cited by applicant
Guardant Health, IPR2022-01158, Paper 33, Exhibit 1066 filed with Petitioner's Reply, Declaration of Dr. Paul T. Spellman (IPR2022-01152) Jun. 30, 2023. cited by applicant
Rusk, N “Uber-accurate sequencing,” Nature Methods, 9, 942-943, Jan. 2012. cited by applicant
EPO, Application No. EP20166917.3, Examination Report, Mail Date: Jul. 20, 2023. 4 pages. cited by applicant
EPO, Application No. EP23178659.1, Extended European Search Report, Sep. 22, 2023, 6 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,175, Notice of Allowance, mail date: Aug. 4, 2023, 14 pages. cited by applicant
USPTO, U.S. Appl. No. 17/392,180, Notice of Allowance, mail date: Aug. 30, 2023, 14 pages. cited by applicant
EPO Boards of Appeal, Communication Forwarding Submission to Parties—Withers & Rogers, Comments in Reponse to Grounds of Appeal, dated Feb. 12, 2024, 153 pages with Annexes I and II. cited by applicant
EPO Boards of Appeal, Communication Forwarding Submission to Parties—Margaret Dixon, Comments in Reponse to Ground pf Appeal, dated Feb. 21, 2024, 50 pages. cited by applicant
EPO Boards of Appeal, Communication Forwarding Submission to Parties—Lewis Silkin, Comments in Response to Grounds of Appeals, dated Feb. 27, 2024, 14 pages. cited by applicant
Caldwell, Randolph B. et al., “Full-length cDNAs from chicken bursal lymphocytes to facilitate gene function analysis,”, Genome Biology, Biomed Central Ltd. vol. 6, No. 1, Dec. 23, 2004, page R6. cited by applicant
EPO, Application No. EP20166917.3, Examination Report, Mail Date: Jan. 23, 2024. 7 pages. cited by applicant
TwinStrand's Letter Brief, TwinStrand Biosciences, Inc., v. Guardant Health, Inc., No. 1:21-1126 (D. Del.) (Oct. 31, 2023), Exhibit F Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
US District Court, Delaware, Claim Construction Order, TwinStrand Biosciences, Inc., v. Guardant Health, Inc., No. 1:21-1126 (D. Del. (Jun. 12, 2023), Exhibit H Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Kircher et al., “Addressing Challenges in the Production and Analysis of Illumina Sequencing Data,” BMC Genomics 12 (2011), Exhibit J Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Infringement Report of Lior Pachter (excerpt), TwinStrand Biosciences, Inc., v. Guardant Health, Inc., No. 1:21-1126 (D. Del) (Apr. 7, 2023), Exhibit N Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Curriculum Vitae of Dr. Peter A Sims, Ex. X Accompanying Request for Exam Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Claim Chart CC-LI, Exhibit AA Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Claim Chart CC-VI, Exhibit BB Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
Declaration of Nathaniel Frank-Wright regarding TruSeq Brochure, Exhibit CC Accompanying Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024. cited by applicant
EPO, Application No. EP20166917.3, Examination Report, Mail Date: Jul. 12, 2024. 5 pages. cited by applicant
Guardant Health, Appellant's Opening Brief—Guardant Health, Inc. v. University of Washington, Appeal No. 24-1129 (appeal of PTAB decision in IPR2022-00817), Apr. 15, 2024. cited by applicant
Guardant Health, Appellant's Reply Brief—Guardant Health, Inc. v. University of Washington, Appeal No. 24-1129 (appeal of PTAB decision in IPR2022-00817), Aug. 5, 2024. cited by applicant
USPTO, U.S. Appl. No. 17/392,203, Notice of Allowance, Examiner David C. Thomas, mail date: Jun. 4, 2024, 13 pages. cited by applicant
USPTO, Order Granting Request For Ex Parte Reexamination of U.S. Pat. No. 10,287,631; Control No. 90/019,551, Mail Date: Aug. 1, 2024, 19 pages. cited by applicant
Bently, David R. et al., Supplemental Information re “Accurate whole human genome sequencing using reversible terminator chemistry,” Nature 456:53-59 (2008). cited by applicant
Illumina, TruSeq RNA and DNA Sample Preparation Kits, Data Sheet: Illumina Sequencing (2010) (IPR2022-00816 Ex. 1012). cited by applicant
EPO, Application No. EP20166917.3, Third Party Observations, Jun. 6, 2024, 3 pages. cited by applicant
Guardant Health, Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024, 130 pages. cited by applicant
Declaration of Dr. Peter A. Sims, Ex. G of Request for Ex Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024, 205 pages. cited by applicant
Illumina, TruSeq RNA and DNA Sample Preparation Kits, Data Sheet: Illumina Sequencing (2010), Exhibit D of Request for Exam Parte Reexam of U.S. Pat. No. 10,287,631, Jun. 21, 2024, 5 pages. cited by applicant
Guardant Health, Opposition to Petition to Vacate Order Granting Reexam of U.S. Pat. No. 10,287,631, Oct. 15, 2024, 17 pages. cited by applicant
EPO, Application No. EP20166917.3, Examination Report, Mail Date: Jan. 14, 2025, 4 pages. cited by applicant

edspgr.12258629